Cells were fixed, stained and imaged as previously described [27 (
link)]. Primary antibodies used were: OCT4 (1;200; Santa Cruz Biotechnology, Dallas, TX, USA; sc-5279),
NANOG (1:100; Abcam, Cambridge, UK; ab21624),
SOX2(Y-17) (1:200; Santa Cruz Biotechnology, Dallas, TX, USA; sc-17320),
TRA-1-60 (1:300; Abcam, Cambridge, UK; ab16288),
NESTIN (1:500; R&D Systems, MAB1259), MUSHASHI (1:500; Abcam, Cambridge, UK; ab21628), FOXA2 (HNF3β) (RY-7; 1:100; Santa Cruz Biotechnology, Dallas, TX, USA; sc-101060), β-3-Tubulin (TUJ1; 1:200; BioLegend, San Diego, CA, USA; 801201) and TH (1:300; Millipore, Burlington, MA, USA; AB152). Secondary antibodies used were:
Alexa Fluor 488 Goat anti-Mouse IgG (H+L; 1:200; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA; A11029),
Alexa Fluor 568 Goat anti-Rabbit IgG (H+L; 1:200; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA; A11036) and Alexa Fluo 647 Donkey anti-Goat IgG (H+L; 1:200; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA; A21447). Image analysis was carried out using Zen Blue confocal software (Carl Zeiss AG, Oberkochen, Germany). All images were processed using Adobe Photoshop CS6 (Adobe Inc. San Jose, CA, USA).
Barbuti P., Antony P., Santos B., Massart F., Cruciani G., Dording C., Arias J., Schwamborn J, & Krüger R. (2020). Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson’s Disease Point Mutation A30P. Cells, 9(9), 2065.